---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-152834"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2026-04-13T23:59:59+00:00"
generated_at: "2026-05-15T06:35:10.494733+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Xenon increases inducement equity plan share reserve from 900k to 1.175M shares

## Summary
- Amended 2025 Inducement Plan to raise maximum shares reserved from 900,000 to 1,175,000, a 30.6% increase.
- Shares are reserved exclusively for inducement grants (nonstatutory options, RSUs, etc.) to new employees.
- Amendment approved by independent directors; shareholder approval not obtained per Nasdaq Rule 5635(c)(4).
- Plan amended effective April 7, 2026; full text filed as Exhibit 10.1.

## SEC filing metadata
- accession: 0001193125-26-152834
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2026-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000119312526152834/0001193125-26-152834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000119312526152834/xene-20260407.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-152834
- JSON: https://secwatch.observer/filing/0001193125-26-152834.json
- Plain text: https://secwatch.observer/filing/0001193125-26-152834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.